Replimune Group Inc (REPL)
Healthcare
Biotechnology
11.20 $
+107.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Replimune Group Inc (REPL)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.0% of the shares are freely tradable; institutional investors hold 96.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
96.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
71.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
49.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
84Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Baker Bros Advisors LP | 13.15 | 11,045,336 | +0.0 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 9.67 | 8,121,433 | -1.7 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 8.76 | 7,356,916 | +3.0 | 03/31/2026 |
| BlackRock Inc | 7.43 | 6,239,239 | +2.8 | 03/31/2026 |
| Suvretta Capital Management, LLC | 5.02 | 4,221,836 | +11,615.0 | 03/31/2026 |
| State Street Corp | 4.50 | 3,782,237 | +2.4 | 03/31/2026 |
| FCPM III SERVICES BV | 3.34 | 2,808,368 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.28 | 2,759,120 | +0.0 | 03/31/2026 |
| D. E. Shaw & Co LP | 2.78 | 2,336,528 | -9.3 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.22 | 2,709,178 | -0.3 | 07/28/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.